MTF Biologics, a nonprofit organisation focused on tissue and organ donation, transplantation, and research, has partnered with Kolosis BIO to release two new allograft tissues aimed at enhancing outcomes in cardiac surgeries.
The collaboration introduces the ATLAS Sternal Repair Matrix and IKON Allograft Surgical Matrix for complex cardiac procedures, addressing essential needs for patient care.
Kolosis BIO CEO Collin Begley said: “For Kolosis, launching ATLAS and IKON in cardiac surgery is an exciting step into a new market, furthering our position as the premier pure-play biologics provider.
“These advanced allografts redefine standards for sternal repair and soft tissue repair, offering surgeons powerful new tools to improve outcomes.”
The ATLAS Sternal Repair Matrix is designed for use in sternal fusion and involves the insertion of a demineralised cortical bone allograft between sternal edges before closure. This product supports the stabilisation and fusion of the sternum in challenging cases.
MTF Biologics processes these allografts to preserve native growth factors, ensuring rapid hydration and bone-forming capacity.
The 3-D architecture of ATLAS is said to provide an ideal osteoconductive environment that facilitates cell adhesion and binding. This matrix is available as a 1×10 cm strip.
The IKON Allograft Surgical Matrix is meant for application within subcutaneous tissue following sternal closure, aiding in incision closure for high-risk patients. It retains growth factors and matrix proteins with a collagen structure conducive to wound management.
The processing technique aims to reduce bacterial growth and inflammation while restoring blood supply. This product is offered in two sizes, 80mg and 160mg.
Both allografts are processed using MTF Biologics’ proprietary aseptic methods, which maintain the integrity of key biological matrices and proteins critical to successful surgical outcomes.
According to MTF Biologics, the two allografts address critical requirements in complex cardiac surgeries, thereby helping in positive patient outcomes.
MTF Biologics vice president and orthopaedic franchise general manager Brad Bailey said: “The MTF Biologics team is pleased to apply our proven allografts, developed in collaboration with surgeons across the nation, to transform sternal fusion and wound healing in the cardiac space.
“ATLAS and IKON will support clinicians caring for patients with complex challenges who are undergoing high-risk cardiac procedures. The Kolosis BIO team is an ideal partner to bring these innovative solutions to this market with us.”
